GSK's Dovato reached the end of the study

GlaxoSmithKline has announced that its two-drug drug Dolutegravir /lamivudine is just as effective in controlling HIV-1 as Vemlidy(Tinofovirafenamide fuma acid) in the TANGO Phase III study.
The study was consistent with its non-poor effectiveness, as well as the 48-week-long main endpoint of the HIV-induced virus suppressed at levels similar to those of Vemlidy.
In the study, none of the patients met the criteria for confirmed virological withdrawal or developed resistance in dolutegravir plus Ramifding combination therapy.
Kimberly Smith, head of global research and medical strategy at ViiV Healthcare, said: "When we conducted the TANGO study, we asked people living with HIV if they could reduce the number of drugs in THEIR treatment options while maintaining viral suppression.
“ These 48-week data clearly show that they can - individuals who have been treated can maintain viral suppression if they change from a treatment program that contains three drugs, including TAF, to a two-drug program that contains multiple drugs and lamif.
earlier this year, Dovato monoliths were licensed in the United States to treat hiv-1 infections in adults with no history of antiretroviral therapy and no known resistance to dolutegravir or lamifding.
It was also approved in Europe in July 2019 for the treatment of HIV-1 infections in adults and adolescents over 12 years of age weighing at least 40 kg.
The full results of the study will be presented at the 10th International AIDS Society AIDS Science Conference. (Compiled by this web)